Brokerages Set Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Price Target at $48.40

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) has been assigned an average recommendation of “Buy” from the seven ratings firms that are presently covering the stock, Marketbeat.com reports. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $48.40.

Several equities research analysts recently weighed in on the company. Truist Financial set a $51.00 target price on Ascentage Pharma Group International in a research note on Monday, November 24th. Piper Sandler assumed coverage on shares of Ascentage Pharma Group International in a research report on Wednesday, November 5th. They set an “overweight” rating and a $48.00 price objective for the company. Rodman & Renshaw started coverage on shares of Ascentage Pharma Group International in a research report on Tuesday, January 13th. They issued a “buy” rating and a $48.00 target price on the stock. BTIG Research assumed coverage on shares of Ascentage Pharma Group International in a research report on Monday, November 10th. They issued a “buy” rating and a $50.00 price target for the company. Finally, Lucid Cap Mkts upgraded shares of Ascentage Pharma Group International to a “strong-buy” rating in a research note on Monday, December 15th.

Ascentage Pharma Group International Stock Down 5.7%

Ascentage Pharma Group International stock opened at $23.20 on Friday. The company has a debt-to-equity ratio of 1.31, a quick ratio of 1.53 and a current ratio of 1.54. The stock’s fifty day moving average is $26.91 and its two-hundred day moving average is $33.84. Ascentage Pharma Group International has a 1-year low of $17.09 and a 1-year high of $48.45.

Institutional Investors Weigh In On Ascentage Pharma Group International

Several large investors have recently modified their holdings of AAPG. Chevy Chase Trust Holdings LLC acquired a new stake in Ascentage Pharma Group International during the 2nd quarter worth $227,000. Tema Etfs LLC acquired a new position in Ascentage Pharma Group International in the second quarter valued at $610,000. UBS Group AG raised its holdings in shares of Ascentage Pharma Group International by 149.4% in the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after buying an additional 10,988 shares during the last quarter. Hsbc Holdings PLC purchased a new stake in shares of Ascentage Pharma Group International in the second quarter valued at about $391,000. Finally, Citadel Advisors LLC acquired a new stake in shares of Ascentage Pharma Group International during the third quarter worth about $383,000.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.